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HIV Basics:
common clinical scenarios
Steven Hatch, MD
USAID PEER/Liberia ID Lecture Series
22 October 2020
Goals
 Review some (not all) clinical scenarios involving 
advanced HIV infection
 Consider some (not all) opportunistic infection (OI) 
scenarios
 Discuss OI prophylaxis
 Discuss alternative HIV regimens
 Briefly review most pertinent data regarding TB/HIV 
coinfection
who.int/hiv/pub/en
34 yo F with shortness of breath
 Sx worsening over last week
 Dry cough
 Fevers and drenching night sweats
 Wt loss ~ 10 lbs
 Vitals: 100.5 F; HR 106; RR 24; O2 sats 95% room air
 Exam: chest & heart auscultation unremarkable
 CBC: WBC 2.2; Hct 29.6; Plt 114
 In ED, O2 sats begin to fluctuate to 84-88%
Which of the following physical findings can help 
you in your diagnosis?
Next steps in management include?
 A. Obtaining HIV test
 B. Blood cultures
 C. Chest X-ray
 D. Pt may be discharged home with clinic follow-up

What is the optimal next step in therapy?
 1. Ceftriaxone 2 grams daily
 2. Gentamicin 6 mg/kg daily
 3. Augmentin IV 
 4. TMP/SMX 15-20/75-100 mg/kg/day divided in 3 doses 
for 5 days
 5. TMP/SMX 5-10/50 mg/kg/day twice daily x 14 days
 6. TMP/SMX 15-20/75-100 mg/kg/day divided in 3 doses 
for 21 days
Pneumocystis Pneumonia
PCP (Pneumocystis jirovecii)
 Initial infection occurs in childhood
 Disease occurs as new infection or reactivation in an 
immunocompromised host
 In the early years of the epidemic, PCP was the most common 
cause of death prior to prevention with trimethoprim-
sulfamethoxazole (USA data)
 90% of disease occurs when CD4 <200 or <14%, so some 
cases of  PCP can occur if  CD4 is >200!
The HIV test is positive. Do you start ART?
 1. No; ART should be started in 8 weeks so she can clear 
the PCP.
 2. No; ART should be started in 2 weeks after she clears.
 3. Yes; ART should be started immediately.
 4. Yes; ART can be started any time between now and 2 
weeks from now.
You choose to start meds immediately. 
Which regimen do you choose?
 1. Emtricitabine, Tenofovir, Abacavir
 2. Lamivudine, Atazanavir, Dolutegravir
 3. Atazanavir, Dolutegravir, Efavirenz
 4. Emtricitabine, Tenofovir, Dolutegravir
 5. Stavudine, Emtricitabine, Tenofovir
aidsinfo.nih.gov
Table 6
https://aidsinfo.nih.gov/contentfiles/lvguidelines/AA_Tables.pdf
Reverse Transcriptase 
Inhibitors (NRTI, “Nukes”)
3TC (lamivudine)
FTC (emtricitabine)
TDF/TAF (tenofovir)
d4T (stavudine)
AZT (zidovudine)
ABC (abacavir)*
Integrase Inhibitors
DTG (dolutegravir)
RAL (raltegravir)*
Protease Inhibitors
ATV (atazanavir)
DRV (darunavir)*
LPV/r (lopinavir)
Treatment options as of 2020 by class
Reverse Transcriptase Inhibitors (NNRTI, or “Non-Nukes”)
EFV (efavirenz)
RPV (rilpiverine)*
NVP (nevirapine)
Recall: “backbone” of standard treatment: 2 NRTIs + EITHER 
Int Inhbitor or PI, or (second line) 2 NRTIs + EFV (NNRTI)

She responds to treatment and is feeling 
better at six months follow-up. When can 
you stop PCP prophylaxis? 
 A. When her CD4 count is > 50
 B. When her CD4 count is > 100
 C. When her CD4 count is > 200
 D. When her CD4 count is > 300
 E. When her CD4 count is >100 and her viral load is 
undetectable for 3-6 months
Time
Acute Retroviral Syndrome (~1-3 months)
CD
4
“AIDS”
(advanced HIV)
CD4 Cell Count 
and Opportunistic 
Infections
“Routine” bacterial PNA
Opportunistic Infection Prophylaxis
 CD4 < 50: Azithromycin 500 mg twice weekly (MAC)
 CD4 < 100 Septra DS one tab daily (toxoplasmosis)
 CD4 < 100 Fluconazole 100 mg daily
 CD4 < 200 Septra SS one tab daily (PCP)
 Any CD4 count: isoniazid 300 mg daily with pyridoxine 25 
mg daily (TB—if no evidence of active TB infection)
 (SS = 80/400 TMP/SMX; DS = 160/800 mg)
40 yo M with headaches
 3 weeks of intense HA sometimes w photophobia 
 Has been somnolent lately. A friend noticed confusion and 
brought him to the ER
 Vitals: Temp 100.2; HR 90; BP: 90/70; eyes closed most 
of the time, sleepy
 Known HIV but may not be taking meds
 Meds: emtricitabine/tenofovir/dolutegravir; TMP/SMX
CT Head
 CSF:
 110 WBC (90% Lymph)
 4 RBC
 Opening pressure 33 cm
 Protein 75
 Glucose 40
Which of the following is true?
 A. this is a space-occupying lesion that will improve with 
resuming his emtricitabine/tenofovir/dolutegravir
 B. this is a space-occupying lesion that will improve with 
changing to stavudine (d4T)/AZT/atazanavir
 C. he may require daily spinal taps
 D. this is an opportunistic organism that will respond to 
treatment with pyrimethamine/sulfadiazine
 E. this is an opportunistic organism that will respond to 
treatment with Septra
Which of the following is the best 
medication to treat this infection?
 A. Fluconazole
 B. Augmentin
 C. Ceftriaxone
 D. Acyclovir
 E. Albendazole
Cryptococcosis
 Highly prevalent in African pts with CD4 < 100 (~10%)
 Clinical: fever, HA, memory loss, altered mentation, 
lethargy
 “Classic” CSF: lymphocytic pleocytosis, mildly elevated 
protein, high opening pressure, crypto Ag +
 BUT CSF can appear unremarkable as well
Treatment Considerations
 (amphotericin B + 
flucytosine)
 Fluconazole ~1200 mg 
daily x 2 wks; 800 mg x 8 
wks
 If ongoing HA or visual 
changes, repeat spinal 
tap(s)
Toxoplasmosis
• Often with more focal
neurologic presentation 
compared to crypto
• CT: typically mult contrast-
enhancing lesions with 
edema
• Seen with PNA and 
retinochoroiditis
• Toxo serology IgG +
• Tx: pyrimethamine + 
sulfadiazine + leucovorin or
clindamycin/pyrimethamine
CNS infections in HIV patients
 Cryptococcosis (usu when CD4 <100)
 Toxoplasmosis (usu when CD4 <100)
 CNS Lymphoma (usu when CD4 <50)
 Progressive Multifocal Leukoencephalopathy (usu when 
CD4 <50)
 Tuberculosis (any CD4 count)
 AIDS dementia (progressive nonspecific CNS changes 
when CD4 <200)
Your eye exam skills can be useful
Toxoplasma CMV retinitis HIV retinopathy
A 20 yo man with fevers x several weeks
 Nonspecific malaise
 Dry cough
 T 102 F; HR 120; BP 100/72; O2 Sats 90%
 Exam: cachectic; systolic murmur across precordium; 
faint diffuse crackles
 CBC: WBC 1.8; Hct 27.8; Plt 214
 Chem: Cr 1.2; Alk Phos 422; Bili 0.7
 HIV spot positive; CD4 returns @ 156
Radiography
Which of the following is true?
 A. He can have only one opportunistic infection, and that 
infection is PCP.
 B. He can have only one opportunistic infection, and that 
is tuberculosis.
 C. He must be treated for TB and complete a six-month 
course before beginning HIV ART.
 D. He should begin HIV ART shortly after starting RIPE 
therapy.
 E. He does not require TMP/SMX while on TB therapy.
TB
 TB can occur @ any stage of HIV
 Increased risk of non-pulmonary presentations (TB 
meningitis; scrofula; Pott’s; peritoneal TB; etc.)
 Start HIV tx within 8 weeks of starting TB tx
 If CD4 < 50, start HIV tx within two weeks
 If TST status in HIV pt is not known and no active TB, 
give INH/pyridoxine for 36 months

Not covered today but critically important
 Non-mycobacterial TB
 Oral and oesophageal candidiasis
 CMV
 HIV-related cancers
 HIV-associated nephropathy (HIVAN)
 How to assess treatment failure
 IRIS
 Much to learn…
